Clinical Report: Copeptin Response to Glucagon Stimulation in Pediatric Patients
Overview
This study investigates the copeptin response to glucagon stimulation in children suspected of growth hormone deficiency. The findings indicate a significant increase in copeptin levels post-glucagon administration.
Background
The diagnostic evaluation of polyuria-polydipsia syndrome (PPS) in children is not well-defined, which can complicate clinical decision-making. Copeptin, a marker of neurohypophysial function, may provide valuable insights in this context. Previous studies have shown robust copeptin responses to glucagon stimulation in adults, but data in pediatric populations remain limited.
Data Highlights
Time (min)
Copeptin Concentration (pmol/L)
Baseline
4.1 (IQR 3.3-6.7)
Peak (150 min)
10.6 (5.4-17.9)
Key Findings
The median baseline copeptin concentration was 4.1 pmol/L.
Copeptin levels peaked at 10.6 pmol/L at 150 minutes post-glucagon injection.
This represents an 87% increase in copeptin concentration from baseline.
No adverse events were reported during the glucagon stimulation test.
The study involved 20 children with an average age of 10.3 years.
Clinical Implications
The glucagon stimulation test appears to be a safe method for enhancing copeptin secretion in children.
Conclusion
The study demonstrates that glucagon stimulation effectively increases copeptin levels in children.
Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.
